Advisors Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$120K Sell
633
-1,014
-62% -$177K ﹤0.01% 1228
2025
Q4
$280K Sell
1,647
-935
-36% -$143K ﹤0.01% 1080
2025
Q3
$340K Sell
2,582
-196
-7% -$23.5K 0.01% 1037
2025
Q2
$295K Sell
2,778
-788
-22% -$85.6K 0.01% 1057
2025
Q1
$443K Sell
3,566
-716
-17% -$93.4K 0.01% 962
2024
Q4
$527K Sell
4,282
-5,342
-56% -$630K 0.01% 910
2024
Q3
$1.07M Buy
9,624
+364
+4% +$39.9K 0.02% 718
2024
Q2
$988K Sell
9,260
-462
-5% -$50.8K 0.02% 734
2024
Q1
$1.17M Buy
9,722
+819
+9% +$100K 0.02% 701
2023
Q4
$1.1M Sell
8,903
-1,116
-11% -$139K 0.02% 702
2023
Q3
$1.3M Buy
10,019
+649
+7% +$86.5K 0.03% 642
2023
Q2
$1.16M Sell
9,370
-2,140
-19% -$288K 0.02% 688
2023
Q1
$1.68M Buy
11,510
+1,220
+12% +$180K 0.03% 574
2022
Q4
$1.64M Buy
10,290
+4,812
+88% +$705K 0.03% 573
2022
Q3
$730K Sell
5,478
-275
-5% -$41.8K 0.02% 830
2022
Q2
$898K Buy
5,753
+328
+6% +$50.5K 0.02% 789
2022
Q1
$845K Buy
5,425
+944
+21% +$137K 0.01% 850
2021
Q4
$571K Buy
4,481
+1,439
+47% +$189K 0.01% 966
2021
Q3
$396K Buy
3,042
+2,218
+269% +$335K 0.01% 1077
2021
Q2
$146K Buy
824
+588
+249% +$102K ﹤0.01% 1253
2021
Q1
$39K Sell
236
-7
-3% -$1.15K ﹤0.01% 1426
2020
Q4
$40K Sell
243
-16
-6% -$2.38K ﹤0.01% 1444
2020
Q3
$37K Sell
259
-2
-0.8% -$248 ﹤0.01% 1431
2020
Q2
$29K Sell
261
-1,941
-88% -$215K ﹤0.01% 1439
2020
Q1
$220K Sell
2,202
-2,349
-52% -$304K 0.01% 1080
2019
Q4
$679K Sell
4,551
-491
-10% -$66.8K 0.01% 891
2019
Q3
$646K Sell
5,042
-2,852
-36% -$382K 0.01% 897
2019
Q2
$1.13M Sell
7,894
-2,064
-21% -$277K 0.02% 737
2019
Q1
$1.42M Sell
9,958
-5,286
-35% -$689K 0.03% 691
2018
Q4
$1.89M Sell
15,244
-577
-4% -$85.6K 0.04% 528
2018
Q3
$2.66M Buy
15,821
+1,496
+10% +$257K 0.04% 491
2018
Q2
$2.47M Sell
14,325
-1,981
-12% -$324K 0.04% 530
2018
Q1
$2.36M Sell
16,306
-506
-3% -$74.2K 0.04% 551
2017
Q4
$2.26M Buy
16,812
+481
+3% +$66.7K 0.04% 576
2017
Q3
$2.39M Sell
16,331
-1,551
-9% -$235K 0.04% 559
2017
Q2
$2.78M Buy
17,882
+86
+0.5% +$13.2K 0.05% 507
2017
Q1
$2.58M Sell
17,796
-5,674
-24% -$739K 0.04% 540
2016
Q4
$2.56M Sell
23,470
-3,035
-11% -$338K 0.04% 555
2016
Q3
$3.22M Sell
26,505
-7,691
-22% -$1.04M 0.05% 483
2016
Q2
$4.83M Sell
34,196
-1,599
-4% -$236K 0.08% 366
2016
Q1
$4.67M Sell
35,795
-5,126
-13% -$638K 0.08% 364
2015
Q4
$5.75M Buy
40,921
+92
+0.2% +$12.7K 0.09% 315
2015
Q3
$5.42M Sell
40,829
-217
-0.5% -$37.4K 0.09% 319
2015
Q2
$7.23M Buy
41,046
+4,558
+12% +$819K 0.1% 272
2015
Q1
$6.3M Buy
36,488
+696
+2% +$119K 0.08% 297
2014
Q4
$5.86M Buy
35,792
+1,358
+4% +$225K 0.08% 309
2014
Q3
$5.53M Buy
34,434
+3,112
+10% +$478K 0.08% 310
2014
Q2
$4.61M Buy
31,322
+3,423
+12% +$475K 0.06% 355
2014
Q1
$3.87M Buy
27,899
+5,692
+26% +$857K 0.06% 375
2013
Q4
$2.81M Buy
22,207
+5,932
+36% +$614K 0.05% 434
2013
Q3
$1.5M Buy
16,275
+4,770
+41% +$385K 0.03% 545
2013
Q2
$791K Buy
+11,505
New +$703K 0.01% 692

Other funds holding JAZZ

Advisors Asset Management's JAZZ Position: Q1 2026 in Review

Advisors Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 62% in Q1 2026, selling an estimated $177K and leaving 633 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #1228.

Advisors Asset Management first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.23M in Q2 2015. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Advisors Asset Management held 633 shares of Jazz Pharmaceuticals worth $120K as of Q1 2026.
  • Advisors Asset Management sold 1,014 Jazz Pharmaceuticals shares in Q1 2026, an estimated $177K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1228 holding.
  • Advisors Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Advisors Asset Management's Jazz Pharmaceuticals position peaked at $7.23M in Q2 2015.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.